 | | Vol. 9.05 – 10 February, 2023 |
| |
|
|
| Glutathione peroxidase 4 was genetically altered in murine models for hepatocellular carcinoma and colorectal cancer (CRC) to analyze the effect of ferroptosis on tumor cells and the immune tumor microenvironment. Subcutaneously grown CRC organoids were utilized.
[Gut] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists found that constitutive activation of autophagy in mice via Beclin 1 enabled the production of a thicker and less penetrable mucus layer by reducing endoplasmic reticulum (ER) stress.
[Cell Host & Microbe] |
|
|
|
| Researchers showed that a subset of patients with inflammatory bowel disease exhibited substantially higher levels of tripartite motif-containing protein 40 (TRIM40), a gene that is hardly detectable in healthy individuals.
[Nature Communications] |
|
|
|
| Investigators demonstrated that mice fed with a Western-style diet suffered regiospecific failure of the mucus barrier in the small intestinal jejunum caused by diet-induced mucus aggregation.
[Cell Reports] |
|
|
|
| Scientists found that RRP15, a nucleolar protein critical for ribosome biogenesis and checkpoint control, was frequently upregulated in primary colorectal cancers (CRCs), and higher RRP15 expression positively correlated with TNM stage and poor survival of CRC patients.
[Cell Death & Disease] |
|
|
|
| Investigators established two radioresistant colorectal cancer (CRC) cell lines, HCT116-R and RKO-R, using fractionated irradiation to explore the role of cancer stem cells in regulating resistance to radiotherapy in colorectal cancer.
[Cell Death Discovery] |
|
|
|
| Researchers revealed the anti-tumor function of pre-B-cell leukemia transcription factor 1 (PBX1) in colorectal cancer and the underlying molecular mechanism.
[Oncogenesis] |
|
|
|
| Scientists showed that BRCA1-associated protein-1 (BAP1) was upregulated in colon cancer cells and tissues and that BAP1 depletion reduced colon cancer cell proliferation and tumor growth.
[Scientific Reports] |
|
|
|
|
| The authors provide an overview of the current knowledge about the genetics of non-monogenic inflammatory bowel disease (IBD) and how it differs from the monogenic forms and future perspectives.
[Human Genetics] |
|
|
|
| | Galapagos NV announced the topline results from DIVERSITY, a global Phase III trial to evaluate the safety and efficacy of filgotinib, 100mg or 200mg once daily, during induction and maintenance treatment of biologic-naïve and biologic-experienced patients with moderate to severe Crohn’s disease.
[Galapagos NV] |
|
|
|
|
| February 22 – 23, 2023
Boston, Massachusetts, United States |
|
|
|
|
|
| | University of Gothenburg – Gothenburg, Sweden |
|
|
|
| | Virginia Commonwealth University – Richmond, Virginia, United States |
|
|
|
| | University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
| | Imperial College London – London, England, United Kingdom |
|
|
|
| | Beckman Research Institute – Monrovia, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
